20-F: ProQR Therapeutics Reports Widening Losses Amid RNA Editing Focus

ProQR Therapeutics N.V. reported increased net losses for 2025, driven by higher R&D costs for its RNA editing platform, while advancing its pipeline and securing partnerships.

Summary

• ProQR Therapeutics N.V. reported a net loss of €42,184,000 for the year ended December 31, 2025, an increase from €27,763,000 in 2024.
• The company's accumulated deficit reached €467,506,000 as of December 31, 2025.
• Cash and cash equivalents stood at €92,413,000 at year-end 2025, down from €149,408,000 in 2024.
• The company expects its existing cash and cash equivalents to fund operations into mid-2027.
• Revenue from the Eli Lilly and Company collaboration decreased to €15,906,000 in 2025 from €18,905,000 in 2024, due to fewer milestones achieved and finalization of certain targets.
• Research and development costs increased to €44,733,000 in 2025 from €36,356,000 in 2024, primarily due to investments in the Axiomer platform and internal pipeline targets.
• General and administrative costs rose to €15,060,000 in 2025 from €13,661,000 in 2024, mainly due to increased employee benefits from senior management changes.
• ProQR is exclusively focused on its proprietary Axiomer RNA editing platform, with lead candidate AX-0810 for cholestatic diseases in Phase 1 clinical trial.
• AX-2402 for Rett Syndrome is advancing to a first-in-human clinical trial in H1 2027, supported by an expanded partnership with Rett Syndrome Research Trust (RSRT) providing $9.2 million in total funding.
• A development candidate for AX-2911 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) targeting PNPLA3 was announced in early 2026.
• The company divested its late-stage ophthalmic assets, sepofarsen and ultevursen, to Laboratoires Tha S.A.S. in December 2023, receiving an initial payment of €8,000,000 and potential earn-out payments up to €165,000,000 plus double-digit royalties.
• ProQR has 105,361,064 ordinary shares outstanding as of December 31, 2025, with potential future dilution from treasury shares, options, and warrants totaling 126,036,800 shares if fully converted.
• The company maintains a one-tier governance structure with a Board of Directors comprising executive and non-executive directors.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for ProQR, marked by increasing losses and cash burn, despite promising early-stage pipeline advancements and strategic partnerships. The financial deterioration outweighs the positive scientific progress in the short term.

Positives

• AX-0810, the lead RNA editing candidate for cholestatic diseases, is in Phase 1 clinical development in healthy volunteers, with preliminary safety and pharmacokinetic data from the first cohort showing no serious adverse events or clinically meaningful laboratory abnormalities.
• The AX-2402 program for Rett Syndrome is advancing towards a first-in-human clinical trial in the first half of 2027, supported by non-clinical proof-of-concept data showing improvements in disease severity in mouse models.
• The partnership with Rett Syndrome Research Trust (RSRT) was significantly expanded in December 2024, providing an additional $8.2 million in funding, bringing total support to $9.2 million for AX-2402.
• A development candidate for AX-2911 for MASH targeting PNPLA3 was announced in early 2026, with non-clinical data demonstrating reduced hepatic fat content in a humanized mouse model.
• The global licensing and research collaboration with Eli Lilly and Company was expanded in December 2022 to include up to ten targets, with an option for five additional targets, and potential milestones up to $3.75 billion plus royalties.
• The company's cash and cash equivalents of €92,413,000 are projected to fund operations into mid-2027, providing a runway for ongoing R&D activities.
• ProQR has a strong intellectual property position in the ADAR editing space, with numerous patent applications filed and granted globally, extending protection to at least 2035-2045.

Negatives

• Net loss significantly increased to €42,184,000 in 2025 from €27,763,000 in 2024, indicating a worsening financial performance.
• The accumulated deficit grew to €467,506,000 by December 31, 2025, reflecting a history of substantial operating losses since inception.
• Cash and cash equivalents decreased by €56,995,000 in 2025, with net cash used in operating activities increasing to €52,791,000.
• Revenue from the Lilly collaboration declined in 2025 due to fewer milestones achieved and finalization of certain targets, highlighting reliance on contingent payments.
• The company has a limited operating history with its refocused RNA editing platform, making future viability and strategy assessment difficult.
• The company will require additional capital to fund operations beyond mid-2027, and there is no certainty that financing will be available on acceptable terms or at all, potentially leading to dilution or scaling back of programs.
• The market price of ordinary shares has been highly volatile, decreasing from a high of $24.99 in 2015 to $0.56 in 2022, indicating significant investment risk.

Risks

• The company has a history of losses and expects to continue incurring significant losses, potentially never achieving or maintaining profitability.
• Additional capital will be required to fund operations, and failure to obtain necessary financing could prevent the completion of product candidate development and commercialization.
• The RNA editing platform and product candidates are in early stages of development and are unproven, with no assurance of successful clinical development, regulatory approval, or commercialization.
• Delays or failures in preclinical studies and clinical trials could increase costs and delay or prevent revenue generation.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable, with no guarantee of obtaining approval for product candidates.
• Collaborative partners may terminate or fail to perform obligations, delaying or terminating product development and commercialization.
• Reliance on third-party manufacturers and suppliers poses risks of supply limitations, interruptions, or quality issues.
• Third parties conducting preclinical and clinical studies may not perform as contractually required, fail to satisfy regulatory requirements, or miss deadlines, delaying development programs.
• The company may become involved in legal proceedings challenging its intellectual property rights, which could be costly and divert management attention.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements, and non-compliance could reduce or eliminate patent protection.
• Third parties may allege infringement of their intellectual property rights, potentially leading to damages, licensing requirements, or cessation of commercialization.
• The company faces intense competition from other pharmaceutical and biotechnology companies with greater resources and experience.
• Even if approved, product candidates may not receive coverage and adequate reimbursement from third-party payors, limiting revenue.
• Inability to attract and retain qualified key management and technical personnel could impair the ability to implement the business plan.
• Significant control by board members and principal shareholders may limit other stakeholders' influence and could delay or prevent a change in corporate control.
• As a foreign private issuer, the company is subject to less stringent U.S. reporting obligations, potentially offering fewer protections to shareholders.
• Unstable market and macroeconomic conditions, including inflation, rising interest rates, and geopolitical events, could adversely affect the business and share price.
• The investment of cash and cash equivalents is subject to market, credit, and liquidity risks, potentially causing losses.
• Exposure to significant foreign exchange risk due to expenses and potential revenues in currencies other than the euro.
• Significant risk of product liability claims from the use of product candidates in studies and potential sales.
• Ability to use net operating losses to offset future taxable income may be limited by Dutch tax law changes.
• Increased attention to ESG initiatives could increase costs, harm reputation, or otherwise adversely impact the business.
• Increasing dependence on information technology systems exposes the company to cybersecurity incidents, data breaches, and data leakage risks.
• The use of new and evolving technologies, such as artificial intelligence, may present security risks to confidential information and intellectual property.

Future Outlook

ProQR expects to continue incurring significant operating losses for the foreseeable future as it invests in its Axiomer platform and advances internal pipeline targets. The company anticipates its current cash and cash equivalents will fund operations into mid-2027, but future capital requirements are uncertain and may necessitate additional financing. The company aims to initiate a first-in-human clinical trial for AX-2402 in the first half of 2027 and expects to report biomarker data for AX-0810 in the first half of 2026. The company also expects increasing levels of regulation related to ESG matters and artificial intelligence, which may increase costs and compliance obligations.

Management Comments

• Management believes that the reappointments of Dr. Shannon and Mr. de Boer to the board were appropriate in light of the company's need for continuity and an appropriately balanced board composition as the company progresses its clinical development activities.
• Management has not identified any going concern risks, based on existing funding, current cash position, and projected cash flows from activities under execution.
• Management's judgment is that convincing evidence for sufficient taxable profits is not currently available, thus deferred tax assets related to operating losses are not recognized.

Industry Context

StockSavvy.ai notes that ProQR's strategic pivot to an exclusive focus on RNA editing positions it in a highly innovative but competitive segment of the biopharmaceutical industry. While RNA editing offers a unique approach to genetic disorders, it is still an unproven technology in many disease indications, increasing development complexity and regulatory uncertainty compared to more established modalities. The company's reliance on collaborations with major pharmaceutical players like Eli Lilly and research trusts like RSRT is a common strategy for smaller biotechs to de-risk and accelerate pipeline development, especially given the substantial capital requirements and high failure rates inherent in drug discovery. The increasing regulatory scrutiny on drug pricing and ESG initiatives, as highlighted in the filing, reflects broader industry trends that will impact all players, particularly those developing high-cost, novel therapies.

Comparison to Industry Standards

• ProQR's accumulated deficit of €467.5 million and continued significant net losses are typical for a clinical-stage biopharmaceutical company investing heavily in novel platform technology and early-stage pipeline development, similar to many peers in the gene and RNA therapy space.
• The cash runway into mid-2027 is within the typical range for biopharmaceutical companies at this stage, which often need to raise capital every 18-24 months to sustain operations and advance programs.
• The expansion of the Eli Lilly collaboration and the RSRT partnership demonstrates external validation of ProQR's Axiomer platform, a common benchmark for success in early-stage biotech, comparable to partnerships seen with companies like Alnylam Pharmaceuticals or Ionis Pharmaceuticals in the oligonucleotide space.
• The high volatility of ProQR's share price ($24.99 high to $0.56 low) is characteristic of the biopharmaceutical sector, where stock performance is heavily influenced by clinical trial results, regulatory milestones, and funding news, similar to companies such as Sarepta Therapeutics or Editas Medicine during their early development phases.
• The company's intellectual property strategy, with multi-tiered patent protection and numerous international filings, aligns with industry best practices for novel technology platforms, aiming to establish a strong competitive moat against potential competitors like Wave Life Sciences or Arrowhead Pharmaceuticals in the RNA therapeutics field.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently facing oppositions in Australia and Europe with respect to patents relating to its Axiomer platform, which could result in loss of patent protection in these jurisdictions if unsuccessful.
• The company may from time to time become involved in legal proceedings with third parties that infringe its intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of its business.
• The company may be subject to claims that it or its employees have wrongfully used or disclosed alleged trade secrets of former employers, which could be costly to defend and result in loss of intellectual property rights or personnel.
• The company may be subject to increased stockholder activism, including potential legal proceedings before the Enterprise Chamber of the Amsterdam Court of Appeal, which could disrupt operations and adversely affect the business.

Related Party Transactions

• Compensation of the Board of Directors and senior management amounted to €7,322,000 in 2025, €5,321,000 in 2024, and €6,398,000 in 2023.
• Eli Lilly and Company is a major shareholder (16.0% ownership) and a collaboration partner, with milestone payments received from them amounting to €3,922,000 in 2025 and €5,096,000 in 2024.
• Van Herk Investments and its affiliates beneficially own 14.6% of ordinary shares.
• Adage Capital Management, L.P. beneficially owns 6.3% of ordinary shares.
• Privium / Stichting Aescap beneficially owns 5.2% of ordinary shares.
• The Rett Syndrome Research Trust (RSRT) is a collaboration partner providing funding and holding warrants to purchase up to 2,144,772 ordinary shares.
• The company has entered into indemnification agreements with all Board members and senior officers.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future capital raises and existing options/warrants. The increasing net losses and cash burn could negatively impact share price and investment value. Concentration of ownership by principal shareholders may limit influence of other stakeholders. As a foreign private issuer, shareholders have different rights compared to U.S. domestic companies.
• **Employees**: Increased R&D activities and focus on the Axiomer platform may create new opportunities, but the company's history of losses and need for future financing could create job uncertainty. Changes in senior management and the departure of key personnel could impact team stability. The company emphasizes fostering empowerment, self-development, creativity, and community.
• **Customers/Patients**: The company's focus on RNA editing for serious diseases with unmet medical needs (cholestatic diseases, Rett Syndrome, MASH) offers potential new therapeutic options. However, the early stage of development means long timelines and no guarantee of marketable products. Regulatory hurdles and market acceptance will determine ultimate patient access.
• **Suppliers/Creditors**: Reliance on third-party manufacturers and CROs means their performance is critical. The company's financial position and need for future funding could impact its ability to meet obligations if not managed effectively. The waiver for the Innovation credit repayment until December 31, 2026, indicates some flexibility with creditors.
• **Regulatory Authorities**: The company is subject to extensive and rigorous review by FDA, EMA, and other authorities. Compliance with evolving regulations, especially for novel RNA technologies and ESG matters, will require significant resources and attention.

Next Steps

• Report data related to biomarkers of NTCP target engagement from AX-0810 healthy volunteer cohorts in the first half of 2026.
• Conduct preparatory activities to include a patient cohort in the AX-0810 Phase 1 trial, subject to regulatory authorization.
• Initiate a first-in-human clinical trial for AX-2402 for Rett Syndrome in the first half of 2027, subject to regulatory authorization.
• Continue to identify and advance additional genetically informed targets through discovery efforts to support long-term growth and pipeline expansion.
• Continue to invest in the optimization of the Axiomer platform, including advances in oligonucleotide design, chemistry, delivery, and data-driven discovery.
• Selectively pursue licensing, partnering, and other strategic relationships to maximize the value of the Axiomer platform.

Key Dates

Recommendation

ProQR Therapeutics is at a critical juncture, having fully pivoted to its RNA editing platform with several promising early-stage candidates and strong partnerships with Eli Lilly and RSRT. While the scientific potential of the Axiomer platform is significant and early clinical data for AX-0810 is positive, the company faces substantial financial headwinds, including widening net losses and a decreasing cash position, necessitating further capital raises. The biopharmaceutical sector is inherently high-risk, with long development timelines and uncertain regulatory outcomes. A 'hold' recommendation reflects the balance between the long-term upside potential of its innovative technology and partnerships, and the immediate financial challenges and execution risks associated with an early-stage pipeline and high cash burn. Investors should monitor clinical trial progress, future financing activities, and the company's ability to manage its increasing operating costs.

Keywords

RNA editing, Axiomer platform, Biotechnology, Pharmaceuticals, Drug development, Preclinical, Clinical trials, Cholestatic diseases, Rett Syndrome, MASH, Eli Lilly, Rett Syndrome Research Trust, Orphan drugs, Intellectual property, Biopharma, Genetic disorders, Therapeutics